Corcept Therapeutics Incorporated (CORT)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 124,557 | 116,191 | 125,006 | 131,602 | 116,676 |
| Revenue | US$ in thousands | 482,375 | 401,858 | 365,978 | 353,874 | 306,486 |
| Pretax margin | 25.82% | 28.91% | 34.16% | 37.19% | 38.07% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $124,557K ÷ $482,375K
= 25.82%
The pretax margin of Corcept Therapeutics Inc has exhibited a downward trend over the past five years, decreasing from 38.07% in 2019 to 25.82% in 2023. This indicates that the company's profitability before taxes has progressively declined. Factors contributing to this decline could include changes in revenue growth, cost structure, or operating efficiency. A declining pretax margin may raise concerns about the company's ability to maintain profitability levels and effectively manage its costs. Further analysis of the company's financial performance and strategies would be necessary to understand the underlying reasons for this trend.
Peer comparison
Dec 31, 2023